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Background: Anatomic and physiological similarities to the human make swine an excellent large animal model
for human health and disease.
Methods: Cloning from a modified somatic cell, which can be determined in cells prior to making the animal,
is the only method available for the production of targeted modifications in swine.
Results: Since some strains of swine are similar in size to humans, technologies that have been developed for
swine can be readily adapted to humans and vice versa. Here the importance of swine as a biomedical model,
current technologies to produce genetically enhanced swine, current biomedical models, and how the completion
of the swine genome will promote swine as a biomedical model are discussed.
Conclusions: The completion of the swine genome will enhance the continued use and development of swine as
models of human health, syndromes and conditions.
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For several decades swine have been a valuable model for
human health and disease [1] and cited in [2]. As a general
rule, animal models for human disease provide researchers
with the knowledge of disease progression, and insights
into new therapies. These potential therapies include drug
discovery, validation, and toxicology but also can be
extended to include gene therapy, surgical interventions
and physical therapy. Rodent models, largely the mouse
but more recently the rat, have been used widely to study
many human health issues [3]. Unfortunately, as in the
case of cystic fibrosis, the rodent models do not always
fully mimic the relevant human symptoms.
Genetic modification is often required to create, or im-
prove the quality of, a model. Gene transfer into the gen-
ome of livestock species was first achieved in 1985 via
pronuclear injection [4]. While this was a tremendous* Correspondence: walterse@missouri.edu
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reproduction in any medium, provided the oradvance, transgenesis by pronuclear injection is limited to
adding a gene(s) at a random location, and has the poten-
tial to cause insertional mutations [5,6] as well as altering
the expression of adjacent host DNA sequences. There
have been many attempts to overcome this problem by in-
sertion of large DNA fragments (YAC or BACs) [7], and
matrix attachment regions or scaffold attachment regions
[8,9]. With the advent of somatic cell nuclear transfer
(SCNT) it became possible to select donor cells with the
desired integration prior to creating the animal. While
SCNT has been useful for transgenesis, the greater advan-
tage is realized when targeting of a gene via homologous
recombination is desired. In mice and recently rats, this is
accomplished through the use of embryonic stem cells.
However, there has been no verified germ-line competent
embryonic stem cell in swine. Despite not having a germ-
line competent ES cell line, investigators have developed
induced pig pluripotent cell lines [10-12] which may prove
to be useful for the production of genetically modified
pigs. Utilizing SCNT seven genes and 1 transgene have
been knocked out in swine: alpha 1, 3 galactosyltransferasel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ance regulator (CFTR; [14,15], Immunoglobulin light chain
kappa (IgLK) [16], Immunoglobulin heavy chain (IgH) [17],
spinal muscle neuron (SMN; [18]), Green Fluorescent
Protein transgene (eGFP; [19]), SIGLEC1 (Whitworth
et al. 2011 unpublished data) and peroxisome proliferator-
activated receptor-gamma (PPARγ); [20], and there are two
knock ins [14]). While the efficiency of cloning still remains
low [21] a complete swine genome will enhance the identi-
fication and modification of genes that are relevant to
human disease. This is especially true for genetic modifica-
tion of existing genes or inserting a transgene at a given lo-
cation. Prior to completion of the swine genome the first
step in developing a construct was to look comparatively at
the sequences of other species. The next step was to search
both assembled and raw data for similar sequences. And fi-
nally the construct could be built. One of the complications
that can arise is the presence or absence of multiple mem-
bers of a gene family. With the latest draft of the genome
completed and the limited annotation associated with it we
have some assurance that there is only a single copy a given
gene, or multiple family members of the gene. A great ex-
ample here is SMN. In humans there are two spinal muscle
neuron genes (SMN1 and SMN2). In pigs there is only a
single gene for spinal muscle neuron. In humans mutations
in both alleles of SMN1 result in reliance on SMN2 and the
development of spinal muscle atrophy (the number one
genetic cause of adolescent mortality in North America).
Thus to make a model of spinal muscle atrophy one must
not only knockout SMN, but also a human SMN2 must be
added as a transgene [18]. Prior knowledge of the number
and location of specific sequences makes these projects
move forward much more rapidly.
Completion of the swine genome will be a key informa-
tional tool for the understanding of human sequences and
their potential role in the development of biomedical
models. Using comparative genomics, we can begin to in-
vestigate and identify cross-species conserved putative
genes and regulatory elements as well as single nucleotide
polymorphism of genes specific to human diseases. As an
example the completion of the human genome, research-
ers were able to identify the gene mutation that caused
sickle cell anemia [22]. Additionally the completion of the
swine genome will be useful in the development of new
techniques such as cell-based transgensis. Utilizing cell
based transgenesis with site specific modification of the
pig genome, one can be begin to modify gene function for
the enhanced development of novel disease models in sev-
eral research areas such as cardiovascular disease, xeno-
transplantation, and neurodegenerative diseases.
Importance of the pig as a biomedical model
Although the classical model organisms have provided
important information about the basic biology of genesand proteins, these models often have limited usefulness
due to their inability to sufficiently represent the human
disease. In addition, there has been a dramatic decline in
the productivity of new drugs [1] which appears to be
associated with the current selection of in vivo models.
The current animal models do not reflect the patho-
physiology of many human diseases well enough to at-
tain sufficient insight into the efficacy of novel drugs,
drug therapy or medical devices; e.g. Cystic Fibrosis
[14,15,23], Spinal Muscle Atrophy [18] and Parkinson’s
Disease [24]. While the pig may not be an obvious
choice for a biomedical model, it has been a top choice
as a model of human health and disease due to the simi-
larities in anatomy, genetics and pathophysiology.
When compared to other large animal models, swine
reach sexual maturity early (6–8 months), have a short
gestation length (~4 months) and give birth to multiple
offspring. Additionally swine are not seasonal breeders
and can therefore produce offspring at any time during
the year. Due to the economic and agricultural import-
ance of swine, there is a great deal of information, and
logistical support on standardized housing, feeding, and
reproductive management and healthcare. Swine also
provide a variety of genetic backgrounds as there are nu-
merous breeds of both standard and miniature pigs that
have been selected to thrive in a variety of environmen-
tal conditions. It may be that the different breeds of
swine will represent the various ethnic groups from vari-
ous regions of the world.
Animal models are essential for insight into etiology
and pathogenesis of human diseases and the develop-
ment of new strategies for disease prevention and treat-
ment. With regard to human anatomy, physiology and
pathophysiology, the pig is a favorable animal model
[25]. Structure and function of the swine gastrointestinal
tract as well as the morphology and pharmacokinetics of
the pancreas are similar to humans [26]. However one
difference between humans and pigs is the lymphatic
system as the cortex and medulla of the swine lymph
node is reversed compared to the human lymph node
[27]. With similarities and differences between pigs and
humans we can begin to utilize genomic tools to analyze
human diseases and the molecular mechanisms of these
diseases in the pig. Previous genetic analysis of the pig
has led to identification of a quantitative trait loci for cu-
taneous melanoma [28], as well as a novel mutation
(Arg to Cys) in the LDL receptor which contributes to
spontaneous hypercholesterolemia [29]. Additionally pig
models have identified markers for puerperal psychosis
[30] and RACK1 as a marker of malignancy for human
melanocytic proliferation [31]. As sequences identified
in the human are associated with specific disease condi-
tions, an immediate search can be conducted to look for
similar genetic variation in the pig. If the variation exists,
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variation does not exist, then a new genetic modification
can be contemplated that would recreate the human
phenotype. With a sequenced pig genome and the devel-
opment of new genetic tools such as SNP chips, investiga-
tors will continue to perform genetic analysis of pig
populations for molecular mechanisms of human diseases.
The pig genome
The pig genome has been sequenced and is currently
being characterized by the Swine Genome Sequencing
Consortium (SGSC) using the hybrid approach combin-
ing hierarchical shotgun sequencing of BAC clones and
whole genome sequencing [32]. By using the 3x coverage
of the BACS and the 3x coverage of the whole genome
approach, the SGSC will be able to construct a 6x cover-
age of the swine genome. Currently the revised assembly
(Sscrofa Build 10) has been released and is available for




The swine genome is comprised of 18 autosomes and
2 sex chromosomes (X and Y chromosomes) and is esti-
mated to be 2.7 Gb. The pig genome is ~7% smaller than
the human, while the mouse and dog genomes are 14%
smaller. In addition to the similarity in size of genome,
there is extensive homology of the swine genome to the
human. On a nucleotide level swine are 3x more similar
to humans than mice are to humans [34]. On average
the synteny blocks of swine-human are farther down the
phylogenetic tree than the mouse or dog [34]. Since there
are larger syntenic blocks between swine and humans,
positional cloning from the pig is generally straight-
forward and local regulatory interactions between en-
hancer regions are more likely conserved.
Methods
Current technologies to produce a TG pig
While generation of germ-line modified swine via embry-
onic stem/germ cell technology has not been reported a
number of other technologies can be used. These include
pronuclear injection [4], oocyte transduction [34,35],
embryo transduction [36,37] fibroblast transduction fol-
lowed by SCNT [35], sperm-mediated gene transfer
(SMGT) [38], fibroblast transfection followed by SCNT
[34,35], and embryonic germ cell transfection followed by
NT [39]. The main advantage of pronuclear injection is
that large constructs can be integrated. The main disad-
vantage of pronuclear injection, oocyte transduction and
SMGT is the lack of control over the site of integration.
The disadvantage of SCNT is that cloning sometimes
results in abnormal animals [13,40] and the efficiencies of
producing offspring is low. In addition, porcine fetalfibroblasts used as SCNT donor cells have a finite prolif-
eration capacity and a lower gene targeting frequency as
compared to embryonic stem cells available in other spe-
cies [41]. Despite these challenges, cloning from a modi-
fied somatic cell is the only method (Figure 1) available
for the production of targeted modifications in swine, and
these modifications can be determined in cells prior to
making the animal [42].
Potential solutions for improving cloning efficiency
have recently focused on the epigenetic regulation of de-
velopment. Completion of the swine genome will be in-
strumental in these efforts. Successful cloning by SCNT
depends on erasure of somatic cell epigenetic modifica-
tions (e.g. histone acetylation and genomic DNA methy-
lation) during pre-zygotic reprogramming, followed by a
post-zygotic establishment of embryonic modifications
that regulate transcription [43,44]. This reprogramming
is critical to the normal development of cloned animals.
Chemical treatments to alter DNA methylation and his-
tone modifications in SCNT donor cells and embryos
are used to shift the genome epigenetic state to more
closely resemble that of a normally fertilized zygote. This
“assisted remodeling” includes the addition of histone
deacetylase inhibitors (HDACi) to donor cell and embryo
culture medium. One example, Trichostatin A (TSA), can
improve in vitro development of SCNT embryos, but TSA
is a known teratogen, and adverse effects on development
and survival have been reported in some species [45].
Other HDACi with lower toxicity such as Scriptaid
[45,46] and sodium butyrate (NaBu; [47]) can markedly
improve pig SCNT embryo development when used
to treat donor cells and embryos, respectively. To mimic
erasure of DNA methylation in donor cells or recon-
structed embryos, 5-aza-20-deoxycytidine (5-aza-dC)
treatment has been used on bovine donor cells prior to
SCNT [48]. This treatment alters the characteristics of the
donor cells but does not enhance development in vitro.
In swine, 5-aza-dC applied to IVF-produced pig zygotes
reveals that DNA of early pig embryos is not subject to ac-
tive demethylation at the pronuclear stage or to passive
demethylation during the cleavage stages [49], as occurs
in the mouse [44]. Such differences in response to chem-
ical treatment among species and stage of development
highlight the variable nature of the cloning procedure on
epigenetic gene regulation (imprinted or non-imprinted).
With the more recent DNA sequencing technologies that
produce millions of reads there is increasing need for a
scaffold to which these reads can be aligned. If these reads
were generated by chromatin immuno-precipitation,
e.g. methylated DNA, or histones with specific post-
translational modifications, then their alignment to a scaf-
fold that has predicted CpG islands and/or transcription
initiation sites would provide insight to regulation of the
development of the cloned (or normal) embryo. It may
Figure 1 The Somatic Cell Nuclear transfer procedure used to create new genetic modifications [35].
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transcriptional profile after, for example, HDACi treat-
ment [50]. Knowledge of the complete pig genome se-
quence will provide a more detailed understanding of this
epigenetic regulation at specific regulatory regions of
genes and enable swine-specific refinement of SCNT
treatments to improve cloning outcomes [21].
Results
Genetically engineered biomedical models
Arguably, the first genetically engineered pigs that mod-
eled a human disorder were produced as an unintended
consequence of an attempt to modify growth in produc-
tion pigs [4]. The growth hormone gene was linked to
the methalothionine promoter in the hope of regulating
growth by alterations of zinc in the diet. Although the
strategy did provide a degree of regulation of the trans-
gene, the basal expression of growth hormone in the
uninduced state was sufficiently high to produce an ac-
romegaly phenotype with associated arthritis symptoms.
Although some researchers suggested a value of these
pigs as a model [51], the transgenic pigs primarily served
to help guide future efforts to manipulate growth in
agricultural settings.
In 1996, the first intentional transgenic pig model of a
human disorder was described for retinitis pigmentosa
(RP) [52]. In this genetic disorder, there is a loss of rod
cells around puberty that results in loss of sensitivevision (“night blindness”). The loss of rods is followed by
the progressive loss of cone cells resulting in loss of per-
ipheral vision that eventually progresses to complete
blindness. When transgenic mice were made with the
mutant gene, they too developed RP [53]. However,
researchers wanted to develop therapeutic interventions
with the goal of maintaining the cone cell population
after the condition has been diagnosed. The mouse ret-
ina, with very few cones, does not provide an adequate
model for this phenomenon. However, the pig has a rod
to cone ratio almost identical to humans. This model
and similar models continues to be used today.
Transgenic pigs will continue to help us to understand
the role of genes, advance pharmacological pharming
and develop organs for xenotransplantation. In addition,
these models will help us to study disease and establish
safety and efficacy of new drugs and procedures. Genetic
engineering in swine presents the opportunity for tar-
geted genetic manipulations. For an exhaustive list of
genetic modifications reported in swine see a review by
Whyte and Prather [54]. Below are a few examples of
where genetically modified swine have provided insight
not otherwise obtainable.
Cystic fibrosis pigs
In 1938, cystic fibrosis (CF) of the pancreas was first
described [55]. Since that time, it has been learned that
many other organs are involved (lung, intestine, liver,
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Cystic Fibrosis is an autosomal recessive disease where
approximately 5% of Caucasians are carriers [57]. Des-
pite identification of the cystic fibrosis transmembrane
conductance regulator (CFTR) anion channel as the
causative gene for CF and having a mouse model where
CFTR has been disrupted [58], for over 20 years, little
advancement has been made in the understanding of
CF. Unfortunately, disruption of CFTR in the mouse
does not result in a human CF phenotype [59-61]. For
those symptoms that are presented in mouse models,
such as the intestinal obstruction phenotype that is
observed in CFTR−/− mice, the presentation differs from
what is observed in humans. In 2008, Rogers et al.
reported the development of CFTR−/− and CFTR ΔF508
swine. Swine were chosen because of their similarity to
humans in their anatomy, biochemistry, life span, and
genetics [56]. Homologous recombination was used to
disrupt CFTR in outbred porcine fibroblast cells. This
followed by SCNT and subsequent matings produced
homozygous CFTR−/− and CFTR ΔF508/ΔF508 animals.
In approximately 15% of human CF patients there is an
intestinal obstruction observed in the first 48 hours after
birth, while in the pig 100% of the animals are affected
[14,15]. In addition to the intestinal phenotype these
pigs further recapitulate the human phenotype by dis-
play of a blocked bile duct, liver lesions, blocked pancre-
atic duct, and a congealed gallbladder [15,62]. These CF
pigs also develop the hallmark phenotype of lung disease
[23] and have led to a better understanding of the
underlying causes of CF in humans. Unexpectedly, the
pig has also led to the identification of low levels of IGF-1
as a possible cause of smaller than average stature among
CF patients [63]. The CF pigs will continue to provide the
necessary understanding for development of drug therap-
ies or treatment that will aid in prevention of the disease.
Prior knowledge from a sequenced genome that there
were not multiple gene family members of CFTR would
have reduced the risk of the overall project.
Xenotransplantation
Xenotransplantation is the transplant of cells, tissues or
organs from one species to another. The number of
people waiting for a suitable organ is over 108,000
(http://www.unos.org/) and there are probably that many
people that could benefit from an organ, but are not ill
enough to get put on the waiting list. Approximately 10
new patients a day are added to the UNOS waiting list
(http://www.unos.org). The number of organ donors for
2009 was only ~14,000. One way to meet the demand by
patients suffering from a wide variety of chronic diseases
and end-stage organ failure may be by xenotransplant-
ation. Swine organs may be able to satisfy the unmet
and clinical need, but preexisting antibodies that recognizean alpha-1-3-galactosyl (α-gal) epitope result in hypera-
cute rejection (HAR; [64]). Within minutes swine cells
or organs transferred to non-human primates, such as
baboons, are destroyed. The α-gal residues are synthesized
by an enzyme, alpha-1,3-galactosyltransferase, which is
encoded by GGTA1. GGTA1 is a pseudogene in humans,
apes, and Old World monkeys; however, GGTA1 is func-
tional in most mammals including the pig. In order to
utilize swine as a model for xenotransplantation, one of
the first obstacles was to remove the α-gal epitopes on the
swine cells by disruption of GGTA1 [13,65-72]. Other
strategies employed to help avoid HAR are the addition of
CD55, and/or CD59 on the GGTA1 background, or
addition of transgenes encoding enzymes to create carbo-
hydrate structures to cover the gal epitope [73]. In
addition to HAR, other genetic modifications have been
made to address cell-mediated, acute humoral xenograft,
and non-vascular rejections as well as the potential cross
species transmission of porcine endogenous retroviruses
(PERV; [73]). PERVs are an integral component of the
swine genome which are ubiquitously expressed and have
has many as 50 proviral loci in the genome depending on
the breed of pigs [74]. The majority of the PERVs are de-
fective and are not disease causing in the pigs [75,76].
There are however currently three replication competent
subclasses of PERVs (PERV A, B, & C) that can infect
either human (PERV A and C) or pig cells (PERV B)
in vitro. With these three subclasses of PERVs that can po-
tentially infect human cells there is a risk of cross
species transmission during xenotranplantation. Con-
cerns of PERV infection during xenotransplantation range
from acceleration of rejection of the xenograft through a
T-cell mediated rejection to providing the necessary se-
quence to convert an endogenous retrovirus to a replica-
tion competent retrovirus [74].
With genetic modifications short term solid organ
xenotransplantation from pig to non-human primate has
been achieved with 2–6 month survival of heterotropic
heart transplants and with life supporting kidney trans-
plant for 3 months [77]. However, lung and liver trans-
plants have not been as successful as the heart and
kidney due to thrombotic microangiopathy and coagula-
tion dysfunction. The next big hurdle for xenotrans-
plantation is the acute vascular rejection (AVR) that
occurs within hours to days after the transplant. AVR is
usually characterized by endothelial activation and cellu-
lar damage from thrombotic microangiopathy [78].
However AVR may be overcome by the utilization of
genetic engineering. Oropeza et al., [78] reported that
the expression of human A20 gene (a TNF-alpha indu-
cible factor) in pigs can provide the protection against
apoptotic and inflammatory stimuli. The ability to pro-
long survival of the pig xenograft appears to be modu-
lated on the ability to produce multi-transgenic pigs
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The completed genome provides information about
the presence and similarity of many of these human
genes in the pig. If a given gene product is predicted
to be highly homologous to the human protein, then
it may not be necessary to add or disrupt that gene for
successful xenotransplantation.
Diabetes
Diabetes mellitus is a group of metabolic disorders char-
acterized by hyperglycemia resulting from impaired in-
sulin secretion or insulin action or a combination of
both. In the physiologic state, the two incretin hormones
glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) enhance insulin secre-
tion in a glucose-dependent manner. GIP and GLP-1 are
secreted from enteroendocrine cells into the blood in re-
sponse to nutrients and bind to their specific G-protein
coupled receptors, GIPR and GLP-1R respectively, on
the pancreatic β-cells. In type 2 diabetic patients the
incretin effect is highly reduced which is mainly related
to an impaired insulinotropic action of GIP while the
insulinotopic action of GLP-1 is preserved [80]. In order
to evaluate the consequences of an impaired GIP action
on glucose control and pancreatic islet integrity, trans-
genic pigs expressing a dominant-negative GIPR (GIPRdn)
in the pancreatic islets were generated [80] by lentiviral
gene transfer [36].
GIPRdn transgenic pigs resemble characteristic features
of human type 2 diabetic patients with impaired insuli-
notropic action of GIP, reduced glucose tolerance and
insulin secretion as well as a reduction of β-cell mass,
and are therefore a relevant model for numerous appli-
cations in basic as well as in translational research. One
area of translational research is the development and pre-
clinical evaluation of incretin-based therapeutics, which is
a very active field of clinical research [81,82]. These in-
clude GLP-1 receptor agonists (GLP-1 analogues and
GLP-1 mimetics) as well as inhibitors of the enzyme
dipeptidyl peptidase-4 (DPP-4) [83], which rapidly degrade
incretin hormones in vivo. Again, a completed genome
will provide the number of family members and similarity
of the members of the glucose homeostasis regulatory
pathway(s). Such knowledge will better direct research to
create better models, treatments and therapies for diseases
such as diabetes.
Discussion
Genetic engineering and genetic tools
Introduction of exogenous DNA into the swine fibro-
blast prior to SCNT or into the pronucleus or early
embryo [84-88] has been performed utilizing several dif-
ferent strategies which have included lipid based delivery
[89,90], viral delivery [13,14,57] and electroporation[65,70,92]. Even though these methods can produce gen-
etically modified swine, these methods utilize random
integration of the exogenous DNA into the swine gen-
ome that occurs utilizing the double strand DNA break
repair system. Since DNA integration employs the
double stranded DNA break repair system, linearized
DNA will integrate 5x greater than supercoiled DNA
[92]. One of the pitfalls of this breakage of plasmid DNA
is that cells could potentially be drug-selected positive
but not express the transgene. In addition, it is thought
that concatamers are more likely to occur with the ran-
dom integration of plasmid DNA which also can poten-
tially silence the transgene [93,94]. Concatamers are head
to tail multicopy gene arrays of the exogenous DNA that
can occur before or during integration [92]. Another
drawback to random integration of exogenous DNA is po-
tential for insertional mutations of the host genome that
may alter the phenotype of the organism [5,6].
Gene targeting is a more precise event than pronuclear
injection as it utilizes specific modifications to the gen-
omic sequence. Gene modification or introduction of
transgenic constructs into the genome of pig donor cells
commonly relies on homologous recombination (HR) as
described originally in mouse ES cells [95-97]. These HR
events can be used to insert large fragments of DNA;
however, to be successful >3 kb of homologous DNA
needs to be used in the targeting vector. Porcine fibro-
blasts can be transfected with a targeting vector contain-
ing the desired mutation. In a small number of cells the
targeting vector pairs with the analogous chromosomal
sequence, introducing the mutation to the genome by
homologous recombination. Cells, screened and identi-
fied as targeted, are then isolated and maintained as a
clonal population. Targeting frequency by HR is only
one in 105-106 cells, even with tissue culture selection
procedures [98].
Gene targeting is a valuable tool for the study of
in vivo gene expression however sometimes these tar-
geted events can be embryonic lethal. There are gen-
etic methods to avoid this embryonic lethality but
still investigate the gene of interest such as inducible
and conditional gene inactivation in a tissue specific
and time specific manner. The Cre/loxP recombinase
system is the most widely used conditional system
[99]. The Cre/lox P system utilizes Cre a 38 kDA re-
combinase from bacteriophage P1 and loxP which is
a 34 bp consensus sequence. The use of lox P sites in
the same orientation will excise any sequence between
them when an active Cre is present [99]. The Cre-lox
system allows for time specific expression of your
transgene in a tissue specific manner if necessary.
The Cre-recombinase system has been confirmed to
be functional in swine cells under physiological condi-
tions (Wells, unpublished).
Figure 2 A series of three Zinc-Finger nuclease (ZFN 1–3) bound to FokI cleavage domain to form a dimer at a sequence specific site
to introduce a double stranded break. The double stranded break introduced by the ZFNs will either repair itself with the Non-homologous
end joining mechanism which results in the deletion of base pairs (1–300 bp) from the gene of interest. Alternatively a linearized construct can
be introduced with the ZFNs and the repair will use the homology directed repair which inserts the transgene.
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well as the alternative splice sites, copy number of the
number of members of a gene family are very important
in developing genetic modifications as described above.
Cell based transgenesis
With the sequenced pig genome, the use of cell based
transgenesis will become a new approach to make genetic-
ally modified pigs. Cell based transgenesis allows investiga-
tors to make more precise genetic modification by utilizing
natural occurring events within the genome such introduc-
tion of double stranded DNA breaks at targeted sites.
Zinc fingers nucleases (ZFNs) [19,100] have been used
recently to target genetic modifications with a high effi-
ciency. ZFNs have been used in mammalian cells to in-
crease the rate and specificity of gene alteration and
transgenesis. ZFNs are synthetic proteins composed of a
nonspecific FokI cleavage domain and multiple Cys2His2
zinc finger DNA-binding domains (Figure 1) [101]. The
binding of two ZFN-FokI heterodimers to two targetsequences on the coding and non-coding DNA strands
with a 6 bp separation allows FokI dimerization and sub-
sequent DNA cleavage. The resulting double strand
break can increase the frequency of HR-mediated gene
targeting by approximately 1000-fold (reviewed in
[102]). Linking zinc fingers in tandem to form modules
allows for the design of highly specific DNA recognition
sequences [103]. The increase in gene targeting by ZFNs
is achieved by the activation of DNA repair mechanisms.
If transgene DNA is co-transfected with ZFNs, repair of
the double strand breaks by HR can result in transgene
insertion in close proximity to the cleavage site as shown
in Figure 2 [104]. In the absence of donor DNA, repair
of the ZFN cut-site by non-homologous end joining
(NHEJ) can inactivate a gene by generating localized
insertions or deletions (Figure 2) [105]. Recently, commer-
cially produced ZFNs (Sigma-Aldrich, Inc. St. Louis, MO)
were used to disrupt a GFP transgene in a primary culture
of porcine fetal fibroblasts [100] which were then used to
create live piglets [19]. In addition PPARγ has been
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of transgenes and/or gene deletions generated by ZFNs in
pig fibroblasts could potentially enhance the efficiency of
transgenic swine by SCNT. Currently there is a large
undertaking of knocking- out 100 genes related to cardio-
vascular and renal disease in the rat genome using ZFNs
or TALENs (Geurts 2011 personal communication).
Recently, there have been several reports of using Trans-
posons for the production of genetically modified organ-
isms such as fish, frogs, mice, rats, and swine [106-112].
Transposons are discrete and mobile sequences in the
genome that do not rely on relationships with other
sequences. In mammalian transgenesis, two transposons
Sleeping Beauty and piggybac have been used for produc-
tion of genetically modified swine [106,107,113,114]. The
transposon system works by having the transgene of inter-
est flanked on both sides with specific terminal repeats
that will be used as transposase recognition sites. Once in
the host cell, transposase will insert the transgene of inter-
est into the host genome. Modifications to this system
have been made to increase the efficiency of the trans-
poson system. Artificial methylation of the transposon,
and preference for the plasmid to be in the supercoiled
conformation results in an increase number of founders
that express the transgene and nearly eliminated the inser-
tion of concatemers into the host genome [115].
Conclusions
The development of genetically engineered pigs for
human health and disease is having a significant impact
on the scientific community as well as improving the de-
velopment of treatments and therapies for human dis-
eases. Currently genetically engineered pig models are
being used for analysis of gene function in various human
diseases, development of new therapeutic strategies as
well as production of biopharmaceutical products. For ex-
ample it is estimated that 60–100 transgenic pigs could
produce enough Factor IX needed for all the hemophilia B
patients in the United States (Velander 2011 personal
communication). Presently, there are 7 genes and 1 trans-
gene that have been knocked out/in swine and more are
being added to this list each year. Genetically engineered
swine modified for specific diseases will permit the inva-
sive monitoring of the development of diseases that previ-
ously were beyond the grasp of physicians who only saw
the disease in humans. The tools are now available to re-
create in swine most any genetic disease that occurs in
humans. These new swine models can then be used to test
interventions pre-clinical and thus reduce any risk for
patients. The completion of the swine genome is provid-
ing the platform for discovering which genes are respon-
sible for various genetic diseases, as well as the tool for
recreating these mutations in swine such as the increased
use of cell based transgenesis in a site specific manner.Competing interests
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